Elliot Norry - 15 Jan 2024 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADAP	Option to purchase Ordinary Shares	Award	$0	+2,544,432		$0	2,544,432	15 Jan 2024	Ordinary Shares	2,544,432	$0.14	Direct	F1, F2
transaction	ADAP	Option to purchase Ordinary Shares	Award	$0	+565,416		$0	565,416	15 Jan 2024	Ordinary Shares	565,416	$0.0013	Direct	F3, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F2	Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028.
F3	The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F4	Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028.
F5	The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.